Canada - Frans - Health Canada

csl behring canada inc - fibrinogène (humaine) - poudre pour solution - 1000mg - fibrinogène (humaine) 1000mg - hemostatics

Chili - Spaans - ISPC (Instituto de Salud Pública de Chile)

laboratorio bagÓ de chile s.a. - fibrinÓgeno humano - fibrinogeno humano 1,000 g - tratamiento de la hemorragia y profilaxis perioperatoria en pacientes con hipo o afibrinogenemia congénita con tendencia a la hemorragia. terapia complementaria para el manejo de la hemorragía severa no controlada en pacientes con hipofibrinogenemia adquirida en curso de la intevención quirúrgica.

Chili - Spaans - ISPC (Instituto de Salud Pública de Chile)

laboratorio bagÓ de chile s.a. - fibrinÓgeno humano - fibrinogeno humano 1,000 g - tratamiento de la hemorragia y profilaxis perioperatoria en pacientes con hipo o afibrinogenemia congénita con tendencia a la hemorgia . "terapia complementaria para el manejo de la hemorragía severa no controlada en pacientes con hipofibrinogenemia adquirida en el curso de la intervención quirúrgica "

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - hepatitis b immunoglobulin, human 160 mg/ml ((>= 98% )as human plasma proteins (exnz)) - solution for injection - 100 iu - active: hepatitis b immunoglobulin, human 160 mg/ml ((>= 98% )as human plasma proteins (exnz)) excipient: glycine water for injection - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (< 10 iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - hepatitis b immunoglobulin, human 160 mg/ml (( >= 98%) as human plasma proteins (ex nz)) - solution for injection - 400 iu - active: hepatitis b immunoglobulin, human 160 mg/ml (( >= 98%) as human plasma proteins (ex nz)) excipient: glycine water for injection - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (< 10 iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - immunoglobulin g 160 mg/ml (immunoglobulin ex nz 16% igg) - solution for injection - 160 mg/ml - active: immunoglobulin g 160 mg/ml (immunoglobulin ex nz 16% igg) excipient: glycine - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - anti-d [rho] immunoglobulin 250 [iu] - solution for injection - 250 iu - active: anti-d [rho] immunoglobulin 250 [iu] - rh(d) immunoglobulin-vf is indicated for the prevention of rh sensitisation in rh(d) negative females at or below child bearing age.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - anti-d [rho] immunoglobulin 625 [iu] - solution for injection - 625 iu - active: anti-d [rho] immunoglobulin 625 [iu] excipient: glycine water for injection - rh(d) immunoglobulin-vf is indicated for the prevention of rh sensitisation in rh(d) negative females at or below child bearing age.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - tetanus immunoglobulin, human 250 [iu] (immunoglobulin ex nz =160mg/ml) - solution for injection - 250 iu - active: tetanus immunoglobulin, human 250 [iu] (immunoglobulin ex nz =160mg/ml) excipient: glycine - tetanus immunoglobulin-vf is indicated for the passive protection of individuals who have sustained a tetanus-prone wound and who have either not been actively immunised against tetanus or whose immunisation history is doubtful. it should also be given to the fully immunised patient with a tetanus-prone wound if more than 10 years have elapsed since the last vaccine dose. in all the above instances, active immunisation with a tetanus vaccine should be commenced at the same time according to current datasheet recommendations.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - zoster immunoglobulin, human 100 iu/ml (immunoglobulin ex nz) - granules for injection - 200 iu/2ml - active: zoster immunoglobulin, human 100 iu/ml (immunoglobulin ex nz) excipient: glycine - zoster immunoglobulin-vf is indicated for prophylaxis against varicella in patients who meet all four of the criteria listed below: 1. one of the following underlying illnesses or conditions: a. neoplastic disease (leukaemia or lymphoma) b. congenital or acquired immunodeficiency c. immunosuppressive therapy with steroids or antimetabolites. 2. one of the following types of exposure to chickenpox or shingles patients: a. household contact b. playmate contact (> 1 hour play indoors) c. hospital contact (in same 2 to 4 bedroom or adjacent beds in a large ward) d. newborn contact (newborn of mother who had onset of chickenpox < 5 days before delivery or within 48 hours after delivery) e. premature infant (> 28 weeks gestation) whose mother lacks a prior history of chickenpox f. premature infant (< 28 weeks gestation or < 1000g) regardless of maternal history. 3. negative or unknown prior history of chickenpox. 4. if zoster immunoglobulin-vf can be administered within 96 hours after exposure. zoster immunoglobulin-vf, normal immunoglobulin-vf (immunoglobulin for intramuscular use) or plasma are of no value in the treatment of established varicella or zoster infection. high levels of circulating antibody do not prevent dissemination of infection. zoster immunoglobulin-vf is not indicated for prophylactic use in immunodeficient children or adults when there is a history of varicella, unless the patient's immunosuppressed status is that which is associated with bone marrow transplantation.